GLP-1 receptor agonists in substance use disorders
In conclusion, BARI-STEP, a randomized, placebo-controlled trial investigating the use of once-weekly semaglutide 2.4 mg in a post-bariatric patient population with a suboptimal clinical response, demonstrates that semaglutide 2.4 mg in patients with a suboptimal clinical response results in substantial, clinically relevant body weight reduction, and improvements in metabolic health and quality of life
b , FSC curves of the final refined model versus the final cryo-EM map (full dataset, black), of the outcome of model refinement with a half map versus the same map (red), and of the outcome of model refinement with a half map versus the other half map (green)
Mild side effects that are observed in patients taking Wegovy are stomach upsets such as nausea, vomiting, diarrhoea or constipation
Therefore, from the maximum dose of 2.4mg, the patient stays on this dose for 4 weeks, then gets reduced to 1.7mg, then 1mg, then 0.5mg, then finally 0.25mg for 4 weeks, and then stops treatment
Eligibility Criteria Inclusion criteria: Full-text original articles
